Benzinga

Benzinga

Benzinga

domingo, agosto 23

Cosmos Health Inc

COSMNASDAQ
Trade with Public
Trade with Public
$0.2215
0.00894.19%
al cierre: Aug 21, 5:00 PM EST
$0.2201
-0.0014-0.63%
After hour: Aug 21, 7:50 PM EST
Ganancias: Los beneficios de Q2 2026 se publicaron el mar ago 18th, después del cierre del mercado
Panorámica generalNoticiasPrevisión de beneficiosFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Cosmos Health Financials

Cosmos Health (COSM) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Cosmos Health Q2 EPS $(0.10) Misses $0.01 Estimate, Sales $18.986M Miss $19.420M Estimate

Cosmos Health (NASDAQ:COSM) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $0.01 by 1100 percent. This is unchanged from the same period last year. The company reported
Benzinga Newsdesk

PRO
Cosmos Health Reports Preliminary Q2 Revenue Of $19.4M, Up 31.5% YoY, H1 Revenue Of $37.3M, Up ~31% YoY

Record Q2 2026 revenue of approximately $19.4 million, up approximately 31.5% year-over-year from $14.75 million in Q2 2025Record first-half 2026 revenue of approximately $37.3 million, up approximately 31% from $28.46
Benzinga Newsdesk

PRO
UPDATE: Cosmos Health Issues Update On U.S. Market Entry Of Its 18 Series Nutraceutical Platform; Projects $22.7M+ Annual U.S. Revenue And $17.0M Gross Profit From 18 Series Nutraceutical Platform At ~75% Margins

Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided an update on its United States market entry through the "18 Series," a
Benzinga Newsdesk

PRO
Cosmos Health Q1 EPS $(0.06) Misses $(0.01) Estimate, Sales $17.928M Miss $21.893M Estimate

Cosmos Health (NASDAQ:COSM) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.01) by 500 percent. This is a 100 percent decrease over losses of $(0.03) per share from the
Benzinga Newsdesk

PRO
Cosmos Health Projects Cur18 Supplement To Generate $2.5M+ Annual Revenue Within 18-Months

Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it is projecting Cur18™ to generate over $2.5 million in
Benzinga Newsdesk

PRO
Cosmos Health Q4 Adj. EPS $(0.04), Inline, Sales $19.703M Beat $18.821M Estimate

Cosmos Health (NASDAQ:COSM) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 91.11 percent increase over losses of $(0.45) per share from the same period last year. The
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved